MICROFLUIDIC DEVISE TO EVALUATE BREAST CANCER STEM CELLS RESPONSE TO CHEMOTERAPY

EDUARDO IMANOL AGÜERO ; DENISE BELGOROSKY ; BETIANA LERNER ; MAXIMILIANO SEBASTIÁN PÉREZ ; ANA MARIA EIJAN

Congreso; Reunion Conjunta de Sociedades de Biociencias SAIC SAI AAFE NANOMED AR 2021; 2021

Introduction: Breast cancer (BC) is the most common tumor in women and a significant cause of cancer-related morbidity and mortality worldwide. The standard treatment depends on several factors including stage, histology and expression of molecular markers. Chemotherapy is widely used for cancer treatment both in the neoadjuvant mode to reduce the tumor mass prior to surgery and in post-surgical adjuvant, however, in some cases the tumors do not respond to treatment. Cancer Stem Cells (CSC) are a minority tumor cell population, associated to chemoresistance. Thus, the development of an in vitro sphere forming assay that can predict CSC treatment response is an important issue for this patients. Microfluidic devices (MD) have surged, in the last decade, as a powerful tool for cell individual study, with the benefit of using a low amount of biological samples. Objective: Evaluate CSC response post-treatment with CT drugs like doxorubicin (Doxo) and paclitaxel (Ptx) using a murine BC mixed cell line (LM38-LP) in conventional culture conditions and in MD. Results: Cancer sphere forming assay, was carried out with or without Doxo or Ptx in both culture support. CT decreased the number of CSCs, measured as sphere formation efficiency (p